|
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Clinical research trials and Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma. Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma  Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
For Condition: recurrent grade 3 follicular lymphoma,recurrent diffuse small lymphocytic/marginal zone lymphoma,recurrent grade 2 follicular lymphoma,recurrent grade 1 follicular lymphoma
Status: Recruiting
Sponsor(s): UAB Comprehensive Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody in treating patients who have relapsed or refractorynon-Hodgkin's lymphoma.
Details: OBJECTIVES: - Determine the maximum tolerated dose of yttrium Y 90 ibritumomab tiuxetan when administered in combination with rituximab in patients with relapsed or refractory low-grade, follicular, or transformed CD20-positive B-cell non-Hodgkin's lymphoma (NHL). - Determine the toxicity of different doses of yttrium Y 90 ibritumomab tiuxetan in patients treated with this regimen. - Determine the frequency of reversal of bone marrow involvement with NHL in patients treated with this regimen. - Determine the antitumor response in patients treated with this regimen. OUTLINE: This is a multicenter, dose-escalation study of yttrium Y 90 ibritumomab tiuxetan. Patients receive rituximab IV once weekly on weeks 1-4. After 4 doses of rituximab, patients without bone marrow involvement and cellularity greater than 50% expected receive rituximab IV once weekly on weeks 6 and 7 and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes with the final dose of rituximab (day 43). Cohorts of 5-6 patients receive escalating dose of yttrium Y 90 ibritumomab tiuxetan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 4 of 5 or 3 of 6 patients experience dose-limiting toxicity. Patients are followed at 6 and 12 weeks, every 2-3 months for 2 years, and then every 6 months for 2 years. PROJECTED ACCRUAL: Approximately 6-30 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 19 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed low-grade, follicular, or transformed CD20-positive B-cell non-Hodgkin's lymphoma (NHL) - Relapsed after prior chemotherapy OR chemotherapy-resistant disease - Failed at least 1 prior chemotherapy regimen - CD20-positive B-cell population in lymph nodes or bone marrow for International Working Formulation A (small lymphocytic lymphoma) and transformed NHL - Bone marrow involvement with lymphoma less than 25% bilaterally - No impaired bone marrow reserve defined as at least 1 of the following criteria: - Prior myeloablative therapies with bone marrow transplantation or peripheral blood stem cell rescue - Platelet count less than 100,000/mm3 - Bone marrow cellularity no greater than 15% - Marked reduction in bone marrow precursors of one or more cell lines (e.g., granulocytic, megakaryocytic, or erythroid) - Failed prior stem cell collection - No CNS lymphoma, chronic lymphocytic lymphoma, or HIV or AIDS-related lymphoma - No diffuse small lymphocytic/marginal zone lymphoma with lymphocyte count greater than 5,000/mm^3 - No pleural effusion NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: Age: - 19 and over Performance status: - WHO 0-2 Life expectancy: - At least 6 months Hematopoietic: - See Disease Characteristics - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hematocrit greater than 30% - Hemoglobin greater than 9.0 g/dL Hepatic: - Bilirubin no greater than 1.5 mg/dL Renal: - Creatinine no greater than 1.5 mg/dL Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 6 months after study participation - No anti-murine antibody reactivity if prior exposure to murine antibodies or proteins - No other primary malignancy - No other serious nonmalignant disease or infection that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy: - See Disease Characteristics - No prior radioimmunotherapy - Prior rituximab allowed if more than 6 months to progression after an objective response - At least 6 weeks since prior rituximab - At least 3 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF) - Recovered from prior immunotherapy Chemotherapy: - See Disease Characteristics - No prior fludarabine - At least 3 weeks since prior anticancer chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered - No concurrent chemotherapy Endocrine therapy: - At least 3 weeks since prior anticancer endocrine therapy - No concurrent high-dose systemic corticosteroids (e.g., 50 mg or more of prednisone as a single dose or 50 mg or less of prednisone for more than 6 doses) Radiotherapy: - No prior radiotherapy to more than 25% of active bone marrow (involved field or regional) - At least 3 weeks since prior anticancer radiotherapy and recovered Surgery: - At least 4 weeks since prior surgery (except diagnostic surgery) and recovered Other: - No other concurrent anticancer therapy - Concurrent oral anticoagulant therapy allowed if platelet count is at least 30,000/mm3
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AndresForero-Torres, Study Chair, UAB Comprehensive Cancer Center
University of Alabama at Birmingham Comprehensive Cancer Center *Recruiting*
Birmingham, Alabama, 35294-3300
United States
Recruiting Andres Forero-Torres 205-934-7167
Mayo Clinic Cancer Center *Recruiting*
Rochester, Minnesota, 55905
United States
Recruiting Gregory Wiseman 507-284-2511
Stanford Cancer Center at Stanford University Medical Center *Recruiting*
Stanford, California, 94305-5302
United States
Recruiting Susan Knox 650-723-5832
Additional Information:
Study ID Numbers: CDR0000069282; UAB-F010806018,NCI-G02-2053,UAB-0127
Study Start Date:
Record last reviewed: April 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00033423
Other Recurrent Grade 2 Follicular Lymphoma Studies:
1. Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
2. Rituximab, Autologous Vaccine Therapy, and Sargramostim in Treating Patients With Recurrent or Refractory Follicular B-Cell Lymphoma
3. Rituximab and Interleukin-2 in Treating Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma That is Refractory to Rituximab
4. Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
5. Vaccine Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma
Related Studies:
Other recurrent grade 2 follicular lymphoma Clinical Trials
Other Alabama Clinical Trials
Other Birmingham Clinical Trials
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
|
|
|
|
|
|
|
